Results 191 to 200 of about 23,218 (270)

Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

, 2019
Chiara Macchi, Maciej Banach, Alberto Corsini, CR Sirtori, Nicola Ferri, Massimiliano Ruscica   +5 more
openalex   +2 more sources

Author Correction: Spatial fibroblast niches define Crohn's fistulae. [PDF]

Nature
McGregor C, Qin X, Jagielowicz M, Gupta T, Yin Z, Lentsch V, Fawkner-Corbett D, Wien Lai V, Gomez Castro P, Bridges E, Lee CH, Chuang HW, Deng L, Aulicino A, Teague R, Moradi S, Park JS, Woo J, Xu K, Tandon R, Cianci N, Bornschein J, Ho LP, Siejka-Zielinska P, Christoforidou Z, Hill S, Lehmann J, Kujawa R, Vargas Gutierrez P, Cheng C, Greco M, Baker K, Bignell M, George B, Fryer E, Vieth M, Antanaviciute A, Simmons A.   +37 more
europepmc   +1 more source

Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency

, 2013
Minna T. Jänis, Kirill V. Tarasov, Hung Xuan Ta, Matti Suoniemi, Kim Ekroos, Reini Hurme, Terho Lehtimäki, Hannu Päivä, Marcus E. Kleber, Winfried März, Annik Prat, Nabil G. Seidah, Reijo Laaksonen   +12 more
openalex   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 [PDF]

Angiology, 2013
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury. [PDF]

Kidney Med
Strimaitis BJ, Francis L, O'Sullivan ED.
europepmc   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source

Retraction Note: In vitro anti-proliferative effects of <i>Zuojinwan</i> on eight kinds of human cancer cell lines. [PDF]

Cytotechnology
Xu L, Qi Y, Lv L, Xu Y, Zheng L, Yin L, Liu K, Han X, Zhao Y, Peng J.   +9 more
europepmc   +1 more source

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)

Frederick Berro Rivera, Sung Whoy, Cruz Linnaeus Louisse, Genquen Philip Carado, John Vincent Magalong, Vincent Anthony Songheng Tang, Mary Grace Enriquez, Martha Gulati, Byambaa Enkhmaa, Neha J. Pagidipati, Nishant Shah   +10 more
openalex   +1 more source